Symbols

CING

Cingulate·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Consensus Rating "Strong Buy"

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CING

Cingulate Inc.

A biopharmaceutical company that develops Precision Timed Release platform to treat Attention Deficit Hyperactivity Disorder

Industry

Pharmaceutical

Established Date

12/14/2012

Listing Date

12/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.cingulate.com

Security Type

Common stock

Office address

1901 W. 47th Place, Kansas City, KS 66205

Business

Introduction

Cingulate Inc., was incorporated in Delaware on December 14, 2012. The Company is a biopharmaceutical company leveraging its proprietary Precise Timed Release Drug Delivery Platform to develop next-generation products for Attention Deficit Hyperactivity Disorder and Anxiety Disorders. Its lead drug candidates CTx-1301 and CTx-1302 are intended as once-daily stimulant drugs for ADHD, while CTx-2103, a once-daily formulation of buspirone, is also being developed for the treatment of anxiety disorders.

Company Financials

EPS

CING has released its 2025 Q4 earnings. EPS was reported at -0.81, versus the expected -0.63, missing expectations. The chart below visualizes how CING has performed over recent quarters, highlighting trends in earnings surprises.